Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 16 to 19 of 19 results for axicabtagene ciloleucel

  1. Epcoritamab for treating relapsed or refractory follicular lymphoma after 2 or more lines of systemic treatment (TA1139)

    Evidence-based recommendations on epcoritamab (Tepkinly) for treating relapsed or refractory follicular lymphoma after 2 or more lines of systemic treatment in adults.

    Technology appraisal guidance
    Published
    11 March 2026
    View recommendations

    Sections for TA1139

  2. Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies (TA559)

    This guidance has been updated and replaced by NICE technology appraisal guidance TA872.

    Withdrawn guidance

  3. Ground-breaking CAR-T therapy to treat aggressive form of blood cancer approved

    More than 400 people set to benefit after NICE recommends first personalised immunotherapy for lymphoma.

    News
    Last updated
    26 January 2024

  4. Two new personalised immunotherapy treatments for aggressive forms of blood cancer recommended for the Cancer Drugs Fund

    NICE recommends two CAR-T therapies, both given as one-off infusions, to treat aggressive forms of blood cancer.

    News
    Last updated
    13 June 2024